influencing the decline of lung function in copd: use of pharmacotherapy

Clicks: 203
ID: 169171
2010
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #29 of 88 articles by views in tijdschrift voor geneeskunde

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Ekaterina S Gladysheva1, Atul Malhotra2, Robert L Owens21Harvard Combined Pulmonary and Critical Care Fellowship, Harvard Medical School, Boston, MA, USA; 2Pulmonary and Critical Care and Sleep Divisions, Brigham and Women’s Hospital, MA, USAAbstract: Chronic obstructive pulmonary disease (COPD) is a common and deadly disease. One of the hallmarks of COPD is an accelerated decline in lung function, as measured by spirometry. Inflammation, oxidative stress and other pathways are hypothesized to be important in this deterioration. Because progressive airflow obstruction is associated with considerable morbidity and mortality, a major goal of COPD treatment has been to slow or prevent the accelerated decline in lung function. Until recently, the only known effective intervention was smoking cessation. However, newly reported large clinical trials have shown that commonly used medications may help slow the rate of lung function decline. The effect of these medications is modest (and thus required such large, expensive trials) and to be of clinical benefit, therapy would likely need to start early in the course of disease and be prolonged. Such a treatment strategy aimed at preservation of lung function would need to be balanced against the side effects and costs of prolonged therapy. A variety of newer classes of medications may help target other pathophysiologically important pathways, and could be used in the future to prevent lung function decline in COPD.Keywords: COPD, emphysema, pulmonary function, beta-agonist, anti-inflammatory, pharmacotherapy in COPD
Reference Key
gladysheva2010internationalinfluencing Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ekaterina S Gladysheva, Atul Malhotra, Robert L Owens
Are you one of these authors? Claim your profile
Journal tijdschrift voor geneeskunde
Year 2010
DOI
DOI not found
URL
http://www.dovepress.com/influencing-the-decline-of-lung-function-in-copd-use-of-pharmacotherap-a4448
Keywords
diseases of the respiratory system

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.